Molecular therapy for Metabolic disorders: MiRNA-208-3p increases (LXR)-α expression, insulin-secreting cell mass and function via down regulation of its target genes, 21/November/2016, 11.04 am

Anti-metastasis therapy: MiRNA-9600 increases the expression of tumor suppressor PTEN and inhibits proliferation, invasion and metastasis of cancer cells via down regulation of its target gene,21/November/2015, 10.38 am
November 21, 2016
Natural product-based PD-1 pathway blockade for Human cancer therapy: γ-Bisabolene, found in Cardamom among others, decreases the expression of Glycogen synthase kinase-3β, increases transcription factor T-bet expression, decreases the abundance of co-inhibitory receptor PD-1 on the cell surface of Cytotoxic-T-cells, increases cytotoxic T lymphocyte function and augments anti-tumor activity, via up-regulation of its target gene, 21/November/2016, 11.17 am
November 21, 2016
Show all

Significance of the study: 

Given that (1)  more than 387 million people worldwide are affected by Diabetes mellitus (DM); (2) the life-long painful injection/drug treatment required to treat DM; and (3) the global economic cost spent for diabetes treatment in 2014 was little more than 600 billion US dollars, there is an urgent need to find: (i)  a way to induce regeneration of adult β-cells that were lost in DM; (ii) a cheaper alternative to the existing expensive drugs; and (iii) a side-effect-free natural product-based drug.

From research findings to therapeutic opportunity:

This study suggests an MiRNA-based Regenerative therapy for DM.  MiRNA-208-3pby decreasing the expression of its target gene it may: (1) increase the expression of modulator of lipid homeostasis liver X receptor (LXR)-α; (2) decrease plasma levels of triglyceride and cholesterol; (3) protect against diet-induced weight-gain; and (4) increase insulin-secreting cell mass and function. price-50

Thereby, it may increase insulin sensitivity and leanness.  Thus, pharmacological formulations encompassing “MiRNA-208-3p or its activators or MiRNA-208-3p plus any of the known anti-metabolic compounds in use”  can be used to treat metabolic disorders, including DM.

Details of the research findings: 

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Terms & Conditions apply

Undisclosed information: How MiRNA-208-3p increases: (1) (LXR)-α expression; (2) and insulin-secreting cell mass and function. 


CitationBoominathan, L., Molecular therapy for Metabolic disordersMiRNA-208-3p  increases (LXR)-α expression, insulin-secreting cell mass and function via down regulation of its target genes, 21/November/2016, 11.04 am, Genome-2-Bio-Medicine Discovery center (GBMD),

Web: or

Courtesy: When you cite drop us a line at

Comments are closed.